Rodrigues, M.; Winkler, K.-K.; Svirydenka, H.; Nilica, B.; Uprimny, C.; Virgolini, I.
Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. Life 2021, 11, 198.
https://doi.org/10.3390/life11030198
AMA Style
Rodrigues M, Winkler K-K, Svirydenka H, Nilica B, Uprimny C, Virgolini I.
Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. Life. 2021; 11(3):198.
https://doi.org/10.3390/life11030198
Chicago/Turabian Style
Rodrigues, Margarida, Kevin-Klaus Winkler, Hanna Svirydenka, Bernhard Nilica, Christian Uprimny, and Irene Virgolini.
2021. "Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE" Life 11, no. 3: 198.
https://doi.org/10.3390/life11030198
APA Style
Rodrigues, M., Winkler, K.-K., Svirydenka, H., Nilica, B., Uprimny, C., & Virgolini, I.
(2021). Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. Life, 11(3), 198.
https://doi.org/10.3390/life11030198
